Sg3 Management, LLC Avadel Pharmaceuticals PLC Transaction History

Sg3 Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$5.46 - $8.29 $262,080 - $397,919	-48,000 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$7.34 - $11.18 $24,317 - $37,039	-3,313 Reduced 6.46%	48,000 $388,000
Q3 2021 Nov 15, 2021	BUY	$6.49 - $9.91 $105,871 - $161,661	16,313 Added 46.61%	51,313 $503,000
Q2 2021 Aug 16, 2021	SELL	$6.73 - $9.05 $100,950 - $135,750	-15,000 Reduced 30.0%	35,000 $236,000
Q1 2021 May 17, 2021	BUY	$6.61 - $10.07 $330,500 - $503,500	50,000 New	50,000 $452,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.